Insulin Delivery Devices Market Size

The global insulin delivery devices market size was valued at USD 34.40 billion in 2025 and USD 58.52 billion by 2035, representing a 5.46% CAGR from 2026 to 2035.

Insulin delivery devices market growth factors

The insulin delivery devices market is being driven by the growing global burden of diabetes, increasing demand for convenient and accurate insulin administration, expansion of home-based healthcare, greater adoption of insulin pens and pumps, and rapid integration of digital technologies into diabetes management. The worldwide diabetes population is creating a larger addressable patient base for insulin administration technologies, while healthcare systems are increasingly emphasizing self-management and continuous monitoring. The transition from conventional syringes toward prefilled pens, reusable smart pens, patch pumps and automated insulin delivery systems is improving convenience and supporting device adoption. Technological developments are another major catalyst, particularly the integration of insulin pumps with continuous glucose monitoring and algorithms capable of adjusting insulin delivery in real time.

The American Diabetes Association’s 2026 standards identify automated insulin delivery systems as the preferred insulin-delivery method over multiple daily injections, conventional continuous subcutaneous insulin infusion and sensor-augmented pumps for many people with type 1 diabetes, while also recommending consideration of AID systems for selected people with type 2 diabetes. Increasing healthcare expenditure, improving reimbursement in developed markets, diabetes screening programs, expanding access to biosimilar insulin, and the growth of disposable and wearable technologies are also strengthening demand.

At the same time, manufacturers are pursuing smaller form factors, lower injection force, improved dosing accuracy, connectivity with smartphones, cloud-based data management and personalized dosing algorithms. In emerging economies, rising awareness and expanding healthcare infrastructure are creating additional opportunities for affordable pens and insulin administration systems, although device costs, reimbursement gaps and uneven access remain important barriers.

Get a Free Sample: https://www.cervicornconsulting.com/sample/2777

What is the insulin delivery devices market?

The insulin delivery devices market comprises technologies used to administer insulin to people with diabetes. Traditional products include insulin syringes, insulin pens and pen needles, while advanced systems include insulin pumps, patch pumps, connected pens and automated insulin delivery systems.

Insulin pens have become particularly important because they combine portability, dosing convenience and relatively simple operation. Disposable prefilled pens eliminate the need for cartridge loading, while reusable pens can reduce recurring device waste and incorporate features such as dose memory.

Insulin pumps provide continuous subcutaneous insulin infusion and can deliver basal and bolus insulin according to programmed or algorithm-driven requirements. Patch pumps remove tubing in some designs, providing a more discreet wearable option.

The market is increasingly converging with the broader diabetes-technology ecosystem. AID systems combine an insulin pump, continuous glucose monitor and algorithm that determines insulin delivery. The ADA describes diabetes technology as now encompassing insulin administration, glucose measurement, automated insulin delivery, connected insulin pens and diabetes-management software.

Why is the insulin delivery devices market important?

The market is important because insulin administration is a continuous requirement for many people with diabetes, particularly those with insulin-dependent diabetes. Device design directly influences how conveniently, accurately and consistently patients can administer insulin.

Modern delivery systems can reduce the burden associated with repeated injections and help integrate insulin administration with glucose monitoring. The ADA notes that automated insulin delivery systems can improve glycemic outcomes and reduce hypoglycemia compared with conventional approaches in appropriate patients.

The importance of affordability is equally significant. WHO emphasizes that diabetes management requires medical devices that are available, affordable, safe and of good quality, while its Global Diabetes Compact includes a target that people with type 1 diabetes should have access to affordable insulin and blood-glucose self-monitoring.

Consequently, the market is not simply about premium technology. It also encompasses scalable pens, syringes and other products that can expand access in emerging and low-resource healthcare systems.

Major companies in the insulin delivery devices market

Novo Nordisk A/S

Company: Novo Nordisk A/S
Specialization: Insulin, GLP-1 therapies and diabetes treatment systems
Key Focus Areas: Prefilled pens, reusable smart pens, insulin formulations, needles and drug-device combinations
Notable Features: FlexTouch, FlexPen, NovoPen 6 and NovoPen Echo Plus
2025 Revenue: DKK 309.064 billion in net sales
Market Share: Company-specific insulin-delivery-device revenue share is not separately disclosed in its 2025 reporting
Global Presence: Products and operations across North America, Europe, Asia-Pacific, China, emerging markets and other international markets.

Novo Nordisk remains one of the most important companies in insulin delivery because of its vertically integrated relationship between insulin formulations and delivery systems. Its portfolio includes prefilled delivery systems such as FlexTouch, FlexPen and InnoLet, durable systems such as NovoPen 6 and NovoPen Echo Plus, and PumpCart cartridges. FlexTouch is designed with features including a non-extending dose button, dose display and an audible end-of-dose click.

The company reported DKK 309.064 billion in 2025 sales, while diabetes-care sales remained broadly stable in Danish kroner and increased 4% at constant exchange rates.

Wockhardt Ltd.

Company: Wockhardt Ltd.
Specialization: Pharmaceuticals, biopharmaceuticals, insulin and insulin analogues
Key Focus Areas: Insulin formulations, biosimilars, reusable and disposable insulin pens
Notable Features: Patented in-house insulin pen technology and integrated biologicals manufacturing
2025 Revenue: ₹3,012 crore revenue from operations in FY2024–25
Market Share: Specific global insulin-delivery-device market share is not publicly disclosed
Global Presence: India and more than 30 international markets in its diabetes business.

Wockhardt represents an important emerging-market participant because it combines insulin manufacturing with proprietary delivery-device development. The company states that it has developed disposable and reusable insulin pens and holds patents covering its insulin-pen technology.

Its FY2024–25 revenue from operations was ₹3,012 crore, up from ₹2,798 crore. Wockhardt has also stated that its diabetes portfolio reaches more than 30 countries.

Medtronic

Company: Medtronic plc
Specialization: Medical technology and diabetes management
Key Focus Areas: Insulin pumps, CGM systems, automated insulin delivery and diabetes consumables
Notable Features: MiniMed 780G AID system and Simplera/Simplera Sync CGM technologies
2025 Revenue: $33.54 billion total company net sales; $2.755 billion from Diabetes
Market Share: Specific global insulin-delivery-device share is not separately disclosed
Global Presence: North America, Europe, Asia-Pacific and other international markets.

Medtronic is particularly significant in the insulin pump and automated insulin delivery segment. Its Diabetes business generated $2.755 billion in fiscal 2025, compared with $2.488 billion in fiscal 2024, representing approximately 11% growth. The company’s 2025 growth was supported by adoption of the MiniMed 780G automated insulin delivery system and international CGM growth.

Medtronic’s strategy illustrates the market’s transition from standalone pumps toward integrated systems in which CGM data informs insulin delivery.

Roche Holding AG

Company: Roche Holding AG
Specialization: Diagnostics, pharmaceuticals and diabetes-management technologies
Key Focus Areas: Insulin delivery, glucose monitoring, digital diabetes management and connected ecosystems
Notable Features: Accu-Chek portfolio, Accu-Chek Solo micropump and digital diabetes-management solutions
2025 Revenue: CHF 61.516 billion group sales
Market Share: Specific insulin-delivery-device share is not separately disclosed
Global Presence: More than 100 markets through Roche Diabetes Care and its broader global organization.

Roche has developed an integrated diabetes-care ecosystem under the Accu-Chek and Roche Diabetes Care brands. Roche Diabetes Care reports more than 40 years of experience, more than 5,500 employees and operations in more than 100 markets.

Its Accu-Chek Solo micropump demonstrates the industry’s move toward tube-free delivery, modular design and integration with digital diabetes-management platforms. Roche also continues to develop connected diabetes technologies; its 2025–2026 roadmap includes expansion of the Accu-Chek SmartGuide CGM solution and integration of CGM data with pen-based insulin delivery systems.

Roche reported CHF 61.516 billion in group sales in 2025, including CHF 13.847 billion from Diagnostics.

Abbott Laboratories

Company: Abbott Laboratories
Specialization: Medical devices, diagnostics, diabetes care and nutrition
Key Focus Areas: Continuous glucose monitoring, connected diabetes management and integration of glucose data with insulin therapy
Notable Features: FreeStyle Libre CGM ecosystem
2025 Revenue: $44.3 billion total sales; Diabetes Care generated $7.6 billion in CGM sales
Market Share: Specific insulin-delivery-device share is not separately disclosed
Global Presence: More than 160 countries.

Abbott is a major participant in the connected diabetes ecosystem, particularly through FreeStyle Libre. Although CGM is technically a glucose-monitoring technology rather than an insulin-delivery device, its increasing integration with insulin pumps and dosing systems makes Abbott strategically important to the insulin-delivery market.

Abbott reported $44.3 billion in full-year 2025 sales, while CGM sales reached $7.6 billion, up from $6.4 billion in 2024. Abbott’s global footprint extends across more than 160 countries.

Important market-share note: The companies above do not consistently disclose standalone insulin-delivery-device market share. Therefore, assigning unsupported percentage shares would be misleading. Their competitive positions are better assessed through product portfolios, device adoption, diabetes-care revenue, geographic reach and technology integration.

Leading trends and their impact

Shift from conventional injections to smart pens

Smart insulin pens are moving beyond simple mechanical dosing. Connected pens can record dose information and transmit it to digital applications, enabling patients and clinicians to review insulin-use patterns.

Novo Nordisk’s NovoPen 6 and NovoPen Echo Plus automatically record insulin dosing information, illustrating how connected functionality is being incorporated into established pen formats.

Impact: Smart pens can improve dose tracking, reduce missed-dose uncertainty and create additional opportunities for software-enabled diabetes management.

Growth of automated insulin delivery

Automated insulin delivery is becoming one of the most transformative areas of the market. These systems combine CGM readings with algorithms to adjust insulin delivery.

The ADA’s 2026 standards identify AID systems as the preferred insulin-delivery method for many people with type 1 diabetes and recommend considering AID for selected people with type 2 diabetes.

Impact: The trend is shifting market competition from individual pumps toward complete ecosystems involving pumps, sensors, algorithms, smartphones and cloud platforms.

Expansion of patch pumps

Tubeless and patch-based pumps address patient concerns around tubing, discretion and portability. Their wearable design makes insulin delivery more compatible with daily activities.

Impact: Patch pumps are expanding the addressable patient population and encouraging companies to compete on comfort, wear time, form factor and ease of use.

Integration of CGM and insulin delivery

CGM is increasingly becoming a core component of advanced insulin delivery. Sensor data can provide the feedback loop required for automated insulin adjustment.

Impact: The competitive landscape is therefore broadening beyond traditional insulin-device manufacturers to include CGM companies, software providers and digital-health businesses.

Home-based diabetes management

The movement toward home healthcare is increasing demand for easy-to-use pens, pumps and connected devices. Market research indicates homecare is becoming a major end-user category.

Impact: Manufacturers are prioritizing simple interfaces, remote monitoring, smartphone connectivity, training resources and smaller wearable designs.

Personalization and AI

Algorithms are increasingly being used to interpret glucose trends and support insulin dosing. China’s 2024–2030 diabetes prevention and control program specifically encourages the use of artificial intelligence, Internet technologies and wearable devices, including pilots involving CGM.

Impact: AI and predictive analytics could enable more personalized dosing and reduce the cognitive burden of diabetes management.

Successful examples of insulin delivery devices around the world

United States: MiniMed 780G automated insulin delivery

Medtronic’s MiniMed 780G represents the evolution of insulin pumps toward automated delivery. Its adoption contributed to Medtronic’s 2025 Diabetes growth, demonstrating the commercial importance of integrated pump-and-CGM ecosystems.

Europe: Roche Accu-Chek Solo

Roche’s Accu-Chek Solo illustrates the European development of modular, tube-free insulin delivery. The micropump can be detached and reattached and supports insulin bolusing from the pump or handheld controller.

Global markets: Novo Nordisk FlexTouch

FlexTouch demonstrates how traditional insulin administration can be improved through ergonomic engineering. Its prefilled design, easy-to-read dose display and audible confirmation are designed to simplify insulin administration.

India and emerging markets: Wockhardt insulin pens

Wockhardt’s reusable and disposable insulin pens demonstrate how domestic manufacturers can combine insulin production with proprietary delivery technologies. The company has developed patented pen technologies and markets its diabetes biological products internationally.

United Kingdom: hybrid closed-loop procurement

The UK’s healthcare system provides an important example of institutional adoption. An NHS Supply Chain framework launched for insulin pumps, CGM and products supporting hybrid closed-loop pathways estimated four-year spending of approximately £960 million to £1.067 billion, excluding VAT.

Global regional analysis, government initiatives and policies shaping the market

North America

North America remains one of the most technologically advanced insulin-delivery markets because of strong adoption of insulin pumps, CGM-linked systems, smart pens and automated insulin delivery.

The United States benefits from established reimbursement infrastructure and significant investment in diabetes technology. Medicare covers durable insulin infusion pumps under Part B when eligibility requirements are met. The Inflation Reduction Act also limits Medicare patient cost-sharing for insulin used in covered durable pumps to $35 for a one-month supply.

The ADA’s technology standards further support the clinical acceptance of AID systems.

Market impact: Reimbursement policies, clinical guidelines and FDA approvals are encouraging manufacturers to develop increasingly integrated insulin-delivery ecosystems.

Europe

Europe is characterized by strong healthcare infrastructure, national reimbursement systems and growing adoption of connected diabetes technologies.

The United Kingdom is particularly notable for NHS adoption of hybrid closed-loop technologies. The NHS procurement framework covering pumps, CGM and hybrid closed-loop products demonstrates growing institutional demand.

European markets are also increasingly emphasizing value-based procurement. In 2025, the UK government announced that NHS medical-technology purchasing would move toward a more patient-focused approach considering effectiveness and value rather than simply selecting the cheapest technology.

Market impact: Public reimbursement and centralized procurement can accelerate adoption while creating stringent requirements for clinical effectiveness, cost-effectiveness and device quality.

Asia-Pacific

Asia-Pacific represents a major long-term opportunity because of its large diabetic population, expanding healthcare infrastructure and increasing awareness of diabetes management.

India

India’s government is strengthening diabetes screening, diagnosis, management and referral through the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD). The program includes population-based screening, early diagnosis and management of diabetes.

The national NCD portal also demonstrates the scale of government-supported diabetes management, with millions of patients under treatment for hypertension and diabetes.

Market impact: Expansion of screening and chronic-disease management can increase the diagnosed population requiring insulin and delivery technologies, while cost sensitivity favors affordable pens, cartridges and reusable devices.

China

China’s Healthy China Action—Diabetes Prevention and Control Action Implementation Plan 2024–2030 establishes targets for diabetes awareness, standardized management and primary-care services. The plan targets diabetes awareness of at least 60% among adults and standardized primary-level management services for at least 70% of people with type 2 diabetes by 2030.

The program also explicitly promotes smart diabetes management using AI, Internet technologies and wearable devices and includes pilots involving continuous glucose monitoring.

Market impact: China’s policy direction is particularly supportive of connected monitoring, digital diabetes management and wearable technologies.

Latin America

Latin American markets are experiencing increasing diabetes-management needs alongside healthcare-access disparities. Growth is likely to be strongest in countries with expanding private healthcare infrastructure, greater availability of modern insulin therapies and improved reimbursement.

The major opportunity is to bridge the gap between advanced insulin delivery technologies and affordability. Manufacturers with scalable disposable and reusable pen platforms can address patients who may not be able to access high-cost automated pump systems.

Market impact: Affordable insulin pens, simplified delivery devices and public-health diabetes programs are likely to remain important market-development tools.

Middle East and Africa

The Middle East and Africa present a mixed market environment. Gulf countries have relatively advanced healthcare systems and growing investment in digital health, while many African markets continue to face affordability and supply-chain challenges.

WHO highlights that access to insulin and associated diabetes devices remains limited in many countries, particularly low- and middle-income economies.

Market impact: The region creates a two-tier opportunity: advanced connected and automated systems in wealthier markets, and affordable syringes, pens and basic delivery technologies in underserved markets.

Global policy direction

At the international level, the WHO Global Diabetes Compact is helping governments focus on prevention, treatment, affordability and access. Its target that all people with type 1 diabetes should have access to affordable insulin and blood-glucose self-monitoring highlights the importance of both medicines and supporting technologies.

WHO’s work on diabetes technologies further emphasizes that devices need to be affordable, available, safe and quality assured.

This policy environment is likely to push the insulin delivery devices industry in two directions simultaneously: premium technology innovation involving automated, connected and wearable systems, and cost-efficient device development aimed at improving insulin access across emerging and underserved markets.

To Get Detailed Overview, Contact Us: https://www.cervicornconsulting.com/contact-us

Read Report: Generative AI in Insurance Market Revenue, Trends, and Strategic Insights by 2035